Baxter touts HDx Theranova data for ‘ extended ’ hemodialysis

Baxter (NYSE:BAX) today released data from 2 independent studies of its novel HDx therapy using the Theranova dialyzer, touting the effective removal of small and mid-sized toxins at similar rates compared to hemodiafiltration. Results from the trial were presented at the 54th Congress of the European Renal Association and European Dialysis and Transplant Association this week, the company said. The Deerfield, Ill.-based company’s HDx therapy uses a Theranova dialyzer designed to extend the range of molecules that it filters from the blood, claiming it “more closely mimics the natural kidney,” according to a press release. The 1st study followed 10 patients over 12-months, with patients receiving HDF therapy for the initial 6 months followed by HDx therapy for the following 6 months. The trial evaluated levels of urea, creatinine, beta-2m and myoglobin in the blood at every 2 months, and found that the HDx therapy was able to clear the 4 molecules associated with kidney failure to a similar extent as the high-volume HDF treatment. Study authors also reported that albumin levels were maintained at similar levels to the HDF therapy period. “Based on our experience, we believe that treatment with the Theranova dialyzer is a good alternative to HDF treatment. We saw that HDx offers equivalent clearance of middle molecules coupled with the operational simplicity of using standard hemodialysis infrastructure, equipment, protocols and staffing. Additionally...
Source: Mass Device - Category: Medical Devices Authors: Tags: Blood Management Clinical Trials Baxter Source Type: news